Alabama warns healthcare providers against use of non-FDA-approved peptides

May 26 (Reuters) - Alabama's ‌medical regulator on ​Tuesday ​warned healthcare providers against prescribing or using so-called research-grade peptides, saying the substances are not ‌approved by the U.S. FDA and may pose ⁠safety risks.

Here are a few details:

• The Alabama Board of Medical ‌Examiners said the peptides ‌have not been tested or reviewed by the U.S. Food and Drug Administration and are not subject ​to oversight on safety, effectiveness or manufacturing standards, making it difficult to verify their contents or assess ⁠potential risks.

• Peptides are short chains of amino acids that act as building ​blocks of proteins and perform essential biological functions in the body.

• In an official notice, ​the board said physicians must ‌only prescribe and dispense drugs obtained from licensed sources and meeting prescription-grade standards, and cannot ⁠use or supply non-FDA-approved peptides under any circumstances.

• The restriction also applies to certified nurse midwives, nurse practitioners and ⁠physician assistants, who are limited to prescribing drugs on approved formularies.

• ​Healthcare providers cannot avoid liability by labeling products as "research-grade" or relying on patient consent forms, the board said, adding that any involvement ‌in recommending, prescribing or administering such substances would violate professional and legal obligations.

• Separately, ‌the FDA is set to convene an advisory panel ⁠in July to consider ‌whether licensed compounding ​pharmacies should be allowed to manufacture certain peptides.

(Reporting by Siddhi Mahatole in Bengaluru; Editing by Shilpi ‌Majumdar)

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Revolution Medicines prices RASONQUE at $39,800 per month
• French security chief sees new threats after Leipzig drone attack
• Brazil lifts forecast for share of interest-rate-linked debt to record high this year